The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's ...

In this phase 2 study, researchers explored whether fecal microbiota transplant could overcome resistance to immune checkpoint inhibition.

Researchers have mapped lung cancer "neighborhoods", finding that cell metabolism is key for determining immunotherapy ...

Patients should be selected for treatment based on the presence of an NRG1 gene fusion in tumor specimens. The Food and Drug Administration (FDA) has granted accelerated approval to Bizengri ® ...

A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...

A meta-analysis of more than 20 phase 3 trials found no clear survival differences by sex or age in metastatic NSCLC but ...

A retrospective study finds that more than one third of patients with stage I-IIIA non-small cell lung cancer do not undergo ...

Ocean Biomedical has announced promising research findings on its cancer immunotherapy candidates, which can enhance the effectiveness of tyrosine kinase inhibitors (TKIs) like osimertinib for ...

The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...

A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...